ReviewFrontiers in immunology2026
Keratinocyte necroptosis in inflammatory skin diseases and acute epidermal injury: mechanisms, evidence, and therapeutic implications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The skin functions as a barrier against external insults and as an active immune organ. Keratinocytes are central to both roles, maintaining epidermal integrity while coordinating cutaneous immune responses. Necroptosis is a lytic form of regulated cell death that can compromise the epidermal barrier and release damage-associated molecular patterns, thereby linking tissue injury to immune activation. Accumulating evidence implicates keratinocyte necroptosis in multiple inflammatory skin diseases and acute epidermal injuries. This mini review summarizes the molecular regulation of keratinocyte necroptosis, critically appraises evidence for its involvement across distinct pathological contexts, and evaluates therapeutic strategies and associated translational challenges. Mechanistic studies and preliminary translational evidence suggest that necroptosis-related signaling in keratinocytes may represent a therapeutic target. However, the effects of pathway modulation may vary across disease contexts and depend on infection status and the immune microenvironment. Defining the disease-specific contribution of keratinocyte necroptosis and the corresponding therapeutic windows will therefore be essential for evaluating the clinical feasibility of this strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.